Brentuximab vedotin (Adcetris) is an anti-CD30 ADC approved as a second or third line therapy for the treatment of Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Here, TNFRSF8 is linked to Hodgkins lymphoma.